Trinity’s technology represents an entirely new approach for the oral delivery of proteins. Previous technologies have attempted to change the body’s natural barrier properties, enhance inactive or dormant pathways, or use devices to assist delivery — hence, these technologies have real, fundamental limits and a narrow therapeutic window.

By contrast, Trinity’s technology utilizes an endogenous trans-cellular pathway — evolved and refined through nature for the express purpose of trans-cellular trafficking.

Furthermore, Trinity's delivery technology does not alter the normal barrier properties of mucosal tissues. Trinity's delivery of macromolecules will dramatically impact patient care and address multiple billion dollar markets.